Newly Developed Gene Classifier Identifies Risk of Breast Pre-Cancer Progression
Published
Written By
Sarah Avery
Director, Duke Health News Office
Topics
Related News
DCI Wins Renewal of NCI Designation, Funding
The Duke Cancer Institute has received the Notice of Award for the renewal of its Cancer Center Support Grant (CCSG) from the National Cancer Institute (NCI), providing funding and reaffirming its position as one of the premier cancer centers in the United States.This recognition underscores the quality and impact of the research, patient care, education, and outreach efforts facilitated by the DCI.Throughout the last CCSG funding period, the DCI has seen an overall increase in high-impact publications and grant funding, specifically by the National Cancer Institute (NCI). The DCI has also increased its clinical trial enrollments, including a 47 percent increase in interventional accruals and a 10 percent increase in therapeutic accruals.Significant scientific highlights from the previous funding period were many, but included:The discovery reported in the journal, Nature, by Chuan-Yuan Li, PhD, that PCSK9 inhibition augments the effectiveness of immunotherapies, leading to currently ongoing clinical trials led by Scott Antonia, MD, PhD, co-leader of the DCI Immuno-Oncology program and director of the DCI Center for Cancer Immunotherapy;A multi-institutional clinical trial testing new targeted therapies for pancreatic cancer published in the New England Journal of Medicine, led by John Strickler, MD, medical oncologist for the DCI Gastrointestinal Cancer disease group and co-leader of the DCI Precision Cancer Medicine and Investigational Therapeutics program; andA multi-center clinical trial led by Daniel George, MD, co-chair for the DCI Center for Prostate and Urologic Cancers, that demonstrated an unexpectedly effective treatment regimen for black men with metastatic prostate cancer.“The CCSG renewal is a testament to our collective strength and shared commitment to making significant strides in the fight against cancer,” said Michael Kastan, MD, PhD, executive director for the DCI. “This provides a strong foundation for continued growth and impact in the years to come.”
Related News
DCI Wins Renewal of NCI Designation, Funding
The Duke Cancer Institute has received the Notice of Award for the renewal of its Cancer Center Support Grant (CCSG) from the National Cancer Institute (NCI), providing funding and reaffirming its position as one of the premier cancer centers in the United States.This recognition underscores the quality and impact of the research, patient care, education, and outreach efforts facilitated by the DCI.Throughout the last CCSG funding period, the DCI has seen an overall increase in high-impact publications and grant funding, specifically by the National Cancer Institute (NCI). The DCI has also increased its clinical trial enrollments, including a 47 percent increase in interventional accruals and a 10 percent increase in therapeutic accruals.Significant scientific highlights from the previous funding period were many, but included:The discovery reported in the journal, Nature, by Chuan-Yuan Li, PhD, that PCSK9 inhibition augments the effectiveness of immunotherapies, leading to currently ongoing clinical trials led by Scott Antonia, MD, PhD, co-leader of the DCI Immuno-Oncology program and director of the DCI Center for Cancer Immunotherapy;A multi-institutional clinical trial testing new targeted therapies for pancreatic cancer published in the New England Journal of Medicine, led by John Strickler, MD, medical oncologist for the DCI Gastrointestinal Cancer disease group and co-leader of the DCI Precision Cancer Medicine and Investigational Therapeutics program; andA multi-center clinical trial led by Daniel George, MD, co-chair for the DCI Center for Prostate and Urologic Cancers, that demonstrated an unexpectedly effective treatment regimen for black men with metastatic prostate cancer.“The CCSG renewal is a testament to our collective strength and shared commitment to making significant strides in the fight against cancer,” said Michael Kastan, MD, PhD, executive director for the DCI. “This provides a strong foundation for continued growth and impact in the years to come.”